This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

POSTER PRESENTATIONS AT ANTIBODY ENGINEERING & THERAPEUTICS EUROPE 2022

Anyone planning to present a poster MUST:

  1. Add the poster presentation add-on option to their conference pass
  2. Submit a poster presentation abstract prior - which must be approved by the Antibody Content Team. You can submit your abstract for approval by clicking this link

All poster presentation abstract submissions will need to be completed and submitted by 13th May, 2022.

POSTER SPECIFICATIONS

In-Person Poster

Please be sure your poster is no bigger than 1 meter (w) x 1.5 meters (h) in portrait orientation.  We cannot guarantee that posters above this size can be accommodated. All in-person poster presenters should also produce a digital version.

Digital Poster

Send your poster in a .PDF format with ideal resolution of 300 dpi to Jade.Monks@informa.com no later than 27 May, 2022. Your poster size should be A4 (8-1/4”x11-3/4” or 210 x297 mm) for scrolling capability.

Poster Topics

  • Polyclonal Antibody Therapeutics: Mechanisms and Perspectives
  • Developing Antibodies to Non-Cancer Indications (Including COVID Antibodies)
  • Alternative Scaffolds (VHH, Nanobodies, Non- IgG, Fibronectin Binders, Peptides)
  • Machine Learning Approaches for Antibody Engineering
  • Strategies for Improving the Therapeutic Window of Antibody Drugs
  • Multispecifics and T-Cell Engagers
  • Finding the Right Antibody (Arrays, MS, Display Technologies)
  • From Antibody Discovery to Screening and Developability